Parvin Asset Management’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$496K Buy
52,500
+12,500
+31% +$100K 0.37% 81
2026
Q2
$350K Hold
40,000
– – 0.27% 96
2026
Q1
$307K Buy
+40,000
New +$274K 0.22% 106

Other funds holding IBRX

Parvin Asset Management's IBRX Position: Q3 2026 in Review

Parvin Asset Management increased its ImmunityBio (IBRX) stake by 31% in Q3 2026, buying an estimated $100K and bringing the position to 52,500 shares worth $496K. The position accounts for 0.37% of the portfolio, ranked #81.

Parvin Asset Management first reported a position in IBRX in Q1 2026 and has held it in 3 quarters since. 407 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • Parvin Asset Management held 52,500 shares of ImmunityBio worth $496K as of Q3 2026.
  • Parvin Asset Management bought 12,500 ImmunityBio shares in Q3 2026, an estimated $100K.
  • ImmunityBio made up 0.37% of Parvin Asset Management's portfolio in Q3 2026, its #81 holding.
  • Parvin Asset Management first reported a position in ImmunityBio in Q1 2026 and has held it in 3 quarters since.
  • 407 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Parvin Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.